In the currently largest approach to identify DDR gene alterations in GI cancers, 17,486 patients with GI cancer were screened and at least one alteration in a subset of 10 DDR genes was identified in 17.1%, with gastric cancer being the most frequently DDR mutated tumor (27.1% had at least one DDR gene mutated), providing a rationale for clinical trials (108) in this specific subset. This evidence concerns the gene DDR1 and neoplasm.